HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Pyxis Oncology (NASDAQ:PYXS) and maintained a price target of $7.
May 16, 2024 | 11:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Pyxis Oncology and maintained a price target of $7, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $7 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100